{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:33:02Z","timestamp":1794641582253,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Virtually delivered healthcare (telehealth, telemedicine) has the potential to reduce gaps in access to opioid agonist therapy (OAT). Barriers to accessing OAT such as lack of transportation, in-person induction requirements, employment demands and limited childcare options reduce treatment opportunities for clients. A completely virtual model of care has been developed in Alberta, Canada. This paper introduces the unique virtual clinic model and describes outcomes from that model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted using datasets within existing electronic health records and databases from Alberta\u2019s Virtual Opioid Dependency Program (VODP). Outcome data were extracted at admission to ongoing care by Case Management within the VODP and at 3, 6 and 12 months for the duration of treatment. Utilization trends over three years were analyzed, including admissions, discharges and active client information. Data regarding clinical outcomes for clients engaged in ongoing care with the VODP were aggregated for analysis over four time periods, including treatment retention rates at 6 and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 440 client records were included in the study sample. Descriptive analysis showed rapid growth in utilization over three fiscal years. Despite rapid growth in utilization, median wait days for treatment decreased from 6 to 0 days with the initiation of a Same Day Start service to support low barrier immediate access to treatment. Treatment retention rates for clients in ongoing care were comparable to published reports, with 90% of the study sample remaining in treatment over 6 months, and 58% showing retention over 12 months. Clients reported high levels of satisfaction (90%) and outcomes reflected reductions in drug use and overdose as well as improved social functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The VODP model demonstrated high levels of client satisfaction, rapid growth in utilization and positive preliminary clinical outcomes. Entirely virtual delivery of opioid agonist therapy is a promising option to facilitate access to evidence based treatment for opioid use disorder (OUD) in the context of a fentanyl overdose crisis, particularly for individuals living in rural or underserved areas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-022-00323-4","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T06:07:09Z","timestamp":1658988429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Virtual opioid agonist treatment: Alberta\u2019s virtual opioid dependency program and outcomes"],"prefix":"10.1186","volume":"17","author":[{"given":"Nathaniel","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-7804","authenticated-orcid":false,"given":"Maureen","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"issue":"9","key":"323_CR1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.mayocp.2018.07.001","volume":"93","author":"YT Yang","year":"2018","unstructured":"Yang YT, Weintraub E, Haffajee RL. Telemedicine\u2019s role in addressing the opioid epidemic. Mayo Clin Proc. 2018;93(9):1177\u201380. https:\/\/doi.org\/10.1016\/j.mayocp.2018.07.001.","journal-title":"Mayo Clin Proc."},{"key":"323_CR2","unstructured":"Public Health Agency of Canada. Opioid-related Harms in Canada. Ottawa: 2020. Health-infobase.canada.ca. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids. Accessed 18 Nov\u00a02020."},{"key":"323_CR3","unstructured":"World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. WHO Press; 2009. https:\/\/www.who.int\/publications-detail\/guidelines-for-the-psychosocially-assisted-pharmacological-treatment-of-opioid-dependence. Accessed 1 Apr\u00a02020."},{"issue":"22","key":"323_CR4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2013tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136. https:\/\/doi.org\/10.1056\/NEJMp1402780.","journal-title":"N Engl J Med"},{"issue":"9","key":"323_CR5","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247-57. https:\/\/doi.org\/10.1503\/cmaj.170958.","journal-title":"CMAJ"},{"key":"323_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/NDT.S39692","volume":"10","author":"S Mauger","year":"2014","unstructured":"Mauger S, Fraser R, Gill K. Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat. 2014;10:587\u201398. https:\/\/doi.org\/10.2147\/NDT.S39692.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"14","key":"323_CR7","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","volume":"54","author":"B Tofighi","year":"2019","unstructured":"Tofighi B, Williams AR, Chemi C, Suhail-Sindhu S, Dickson V, Lee JD. Patient barriers and facilitators to medications for opioid use disorder in primary care. Subst Use Misuse. 2019;54(14):2409\u201319.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"323_CR8","doi-asserted-by":"publisher","first-page":"e13173","DOI":"10.7759\/cureus.13173","volume":"13","author":"K Patel","year":"2021","unstructured":"Patel K, Bunachita S, Agarwal AA, Lyon A, Patel UK. Opioid use disorder: treatments and barriers. Cureus. 2021;13(2):e13173. https:\/\/doi.org\/10.7759\/cureus.13173.","journal-title":"Cureus."},{"issue":"7","key":"323_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in canada 20 years after federal oversight. Can J Psychiatry. 2017;62(7):444\u201350. https:\/\/doi.org\/10.1177\/0706743717711167.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"323_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/JFN.0000000000000221","volume":"14","author":"JL McIntyre","year":"2018","unstructured":"McIntyre JL. Combatting the opioid crisis from prison: initiating opioid agonist therapy. J Forensic Nurs. 2018;14(4):248\u201352. https:\/\/doi.org\/10.1097\/JFN.0000000000000221.","journal-title":"J Forensic Nurs"},{"key":"323_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2018.09.003","volume":"193","author":"N Bozinoff","year":"2018","unstructured":"Bozinoff N, DeBeck K, Milloy MJ, et al. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada. Drug Alcohol Depend. 2018;193:42\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.09.003.","journal-title":"Drug Alcohol Depend"},{"key":"323_CR12","unstructured":"Wells C, Dolcine B, Frey N. Programs for the Treatment of Opioid Addiction: An Environmental Scan. Ottawa: CADTH; 2019. (no. 87). https:\/\/cadth.ca\/sites\/default\/files\/es\/es0335-programs-for-treatment-opioid-addiction-in-Canada.pdf. Accessed 1 Apr\u00a02020."},{"key":"323_CR13","doi-asserted-by":"publisher","first-page":"108163","DOI":"10.1016\/j.jsat.2020.108163","volume":"120","author":"JMW Hughto","year":"2021","unstructured":"Hughto JMW, Peterson L, Perry NS, et al. The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19. J Subst Abuse Treat. 2021;120:108163.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"323_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","volume":"71","author":"SC Sigmon","year":"2014","unstructured":"Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359\u201360. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.4450.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"323_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1089\/tmj.2013.0075","volume":"19","author":"DM Hilty","year":"2013","unstructured":"Hilty DM, Ferrer DC, Parish MB, Johnston B, Callahan EJ, Yellowlees PM. The effectiveness of telemental health: a 2013 review. Telemed J E Health. 2013;19(6):444\u201354. https:\/\/doi.org\/10.1089\/tmj.2013.0075.","journal-title":"Telemed J E Health"},{"issue":"4","key":"323_CR16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s11414-018-9611-1","volume":"46","author":"H Mahmoud","year":"2019","unstructured":"Mahmoud H, Vogt E. Telepsychiatry: an innovative approach to addressing the opioid crisis. J Behav Health Serv Res. 2019;46(4):680\u20135. https:\/\/doi.org\/10.1007\/s11414-018-9611-1.","journal-title":"J Behav Health Serv Res"},{"key":"323_CR17","doi-asserted-by":"publisher","unstructured":"LaBelle B, Franklyn AM, Pkh Nguyen V, Anderson KE, Eibl JK, Marsh DC. Characterizing the use of telepsychiatry for patients with opioid use disorder and cooccurring mental health disorders in Ontario, Canada. Int J Telemed Appl. 2018.\u00a0https:\/\/doi.org\/10.1155\/2018\/7937610.","DOI":"10.1155\/2018\/7937610"},{"key":"323_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13722-015-0035-4","volume":"10","author":"T Molfenter","year":"2015","unstructured":"Molfenter T, Boyle M, Holloway D, Zwick J. Trends in telemedicine use in addiction treatment. Addict Sci Clin Pract. 2015;10:14. https:\/\/doi.org\/10.1186\/s13722-015-0035-4.","journal-title":"Addict Sci Clin Pract"},{"issue":"Suppl 1","key":"323_CR19","doi-asserted-by":"publisher","first-page":"A40","DOI":"10.1186\/1940-0640-10-S1-A40","volume":"10","author":"T Molfenter","year":"2015","unstructured":"Molfenter T. The pressing shortage of buprenorphine prescribers and the pending role of telemedicine. Addict Sci Clin Pract. 2015;10(Suppl 1):A40. https:\/\/doi.org\/10.1186\/1940-0640-10-S1-A40.","journal-title":"Addict Sci Clin Pract."},{"issue":"9","key":"323_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/1357633X17730444","volume":"24","author":"J Shaw","year":"2018","unstructured":"Shaw J, Jamieson T, Agarwal P, Griffin B, Wong I, Bhatia RS. Virtual care policy recommendations for patient-centred primary care: findings of a consensus policy dialogue using a nominal group technique. J Telemed Telecare. 2018;24(9):608\u201315.","journal-title":"J Telemed Telecare"},{"key":"323_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsat.2019.03.007","volume":"101","author":"LA Lin","year":"2019","unstructured":"Lin LA, Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. Telemedicine-delivered treatment interventions for substance use disorders: A systematic review. J Subst Abuse Treat. 2019;101:38\u201349. https:\/\/doi.org\/10.1016\/j.jsat.2019.03.007.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"323_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jama.2019.12574","volume":"322","author":"R Rubin","year":"2019","unstructured":"Rubin R. Using telemedicine to treat opioid use disorder in rural areas. JAMA. 2019;322(11):1029\u201331. https:\/\/doi.org\/10.1001\/jama.2019.12574.","journal-title":"JAMA"},{"key":"323_CR23","unstructured":"Bruneau J, Rehm J, Wild TC, et al. Telemedicine Support for Addiction Services: National Rapid Guidance Document. Montreal, Quebec: Canadian Research Initiative in Substance Misuse; 2020.\u00a0Version 1. https:\/\/crism.ca\/wp-content\/uploads\/2020\/05\/CRISM-National-Rapid-Guidance-Telemedicine-V1.pdf. Accessed 18 Nov\u00a02020."},{"key":"323_CR24","unstructured":"U.S. Drug Enforcement Agency, Diversion Control Division. COVID-19 Information Page. Accessed 17 Dec\u00a02021. https:\/\/www.deadiversion.usdoj.gov\/coronavirus.html."},{"key":"323_CR25","doi-asserted-by":"publisher","first-page":"108272","DOI":"10.1016\/j.jsat.2020.108272","volume":"124","author":"L Wang","year":"2021","unstructured":"Wang L, Weiss J, Ryan EB, Waldman J, Rubin S, Griffin JL. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abuse Treat. 2021;124:108272.","journal-title":"J Subst Abuse Treat"},{"key":"323_CR26","doi-asserted-by":"publisher","first-page":"108283","DOI":"10.1016\/j.jsat.2021.108283","volume":"124","author":"SA Clark","year":"2021","unstructured":"Clark SA, Davis C, Wightman RS, Wunsch C, Keeler LAJ, Reddy N, et al. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. J Subst Abuse Treat. 2021;124:108283.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"323_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JAN.0000000000000419","volume":"32","author":"DJ Moore","year":"2021","unstructured":"Moore DJ, Goyal D, Rodriguez L. Experiences of opioid use disorder patients receiving buprenorphine through a telehealth program. J Addictions Nurs. 2021;32(3):205\u201310.","journal-title":"J Addictions Nurs"},{"issue":"1","key":"323_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68. https:\/\/doi.org\/10.1186\/s13722-021-00275-1.","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"323_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1089\/tmj.2021.0308","volume":"28","author":"AG Guillen","year":"2022","unstructured":"Guillen AG, Reddy M, Saadat S, Chakravarthy B. Utilization of telehealth solutions for patients with opioid use disorder using buprenorphine: a scoping review. Telemed J E Health. 2022;28(6):761\u20137. https:\/\/doi.org\/10.1089\/tmj.2021.0308.","journal-title":"Telemed J E Health"},{"key":"323_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","volume":"176","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Gauthier G, Pellegrini D, et al. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017;176:133\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.01.048.","journal-title":"Drug Alcohol Depend"},{"key":"323_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000513471","volume":"27","author":"K Morin","year":"2021","unstructured":"Morin K, Parrotta MD, Eible JK, Marsh D. A retrospective cohort study comparing in-person and telemedicine-based opioid agonist treatment in Ontario, Canada, using administrative health data. Eur Addict Res. 2021;27:268\u201376. https:\/\/doi.org\/10.1159\/000513471.","journal-title":"Eur Addict Res"},{"issue":"2","key":"323_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"323_CR33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. New York: American Psychiatric Publishing; 2013.","edition":"5"},{"key":"323_CR34","unstructured":"Lawrinson P, Copeland J, Indig D. The Brief Treatment Outcome Measure: Opioid Maintenance Pharmacotherapy (BTOM) Manual. Sydney: National Drug and Alcohol Research Centre Technical Report; 2003. (no. 156). https:\/\/ndarc.med.unsw.edu.au\/sites\/default\/files\/ndarc\/resources\/TR.156.PDF. Accessed 17 July\u00a02020."},{"issue":"1","key":"323_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.drugalcdep.2005.04.001","volume":"80","author":"P Lawrinson","year":"2005","unstructured":"Lawrinson P, Copeland J, Indig D. Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy services: the brief treatment outcome measure (BTOM). Drug Alcohol Depend. 2005;80(1):125\u201333. https:\/\/doi.org\/10.1016\/j.drugalcdep.2005.04.001.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"323_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/ADM.0000000000000287","volume":"11","author":"W Zheng","year":"2017","unstructured":"Zheng W, Nickasch M, Lander L, et al. Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for Opioid Use Disorder: A 2-year retrospective data analysis. J Addict Med. 2017;11(2):138\u201344. https:\/\/doi.org\/10.1097\/ADM.0000000000000287.","journal-title":"J Addict Med"},{"issue":"8","key":"323_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/ajad.12805","volume":"27","author":"E Weintraub","year":"2018","unstructured":"Weintraub E, Greenblatt AD, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27(8):612\u20137. https:\/\/doi.org\/10.1111\/ajad.12805.","journal-title":"Am J Addict"},{"issue":"2","key":"323_CR38","first-page":"5","volume":"23","author":"E Weintraub","year":"2021","unstructured":"Weintraub E, Greenblatt AD, Chang J, et al. Outcomes for patients receiving telemedicine-delivered medication-based treatment for Opioid Use Disorder: A retrospective chart review. Heroin Addict Relat Clin Probl. 2021;23(2):5\u201312.","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"5","key":"323_CR39","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: A systematic review. PLoS One. 2020;15(5):e0232086. https:\/\/doi.org\/10.1371\/journal.pone.0232086.","journal-title":"PLoS One."},{"key":"323_CR40","doi-asserted-by":"publisher","first-page":"108005","DOI":"10.1016\/j.drugalcdep.2020.108005","volume":"212","author":"H Dong","year":"2020","unstructured":"Dong H, Hayashi K, Milloy MJ, et al. Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug Alcohol Depend. 2020;212:108005.","journal-title":"Drug Alcohol Depend."},{"key":"323_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drugpo.2017.07.009","volume":"49","author":"L Wang","year":"2017","unstructured":"Wang L, Min JE, Krebs E, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017;49:32\u201340.","journal-title":"Int J Drug Policy."},{"issue":"2","key":"323_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.drugalcdep.2006.03.004","volume":"84","author":"S Darke","year":"2006","unstructured":"Darke S, Williamson A, Ross J, et al. Reductions in heroin use are not associated with increases in other drug use: 2-year findings from the Australian Treatment Outcome Study. Drug Alcohol Depend. 2006;84(2):201\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"323_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/ADM.0000000000000726","volume":"15","author":"BR Ford","year":"2021","unstructured":"Ford BR, Bart G, Graham B, Shearer RD, Winkelman TNA. Associations between polysubstance use patterns and receipt of medications for opioid use disorder among adults in treatment for opioid use disorder. J Addict Med. 2021;15(2):159\u201362.","journal-title":"J Addict Med"},{"issue":"9","key":"323_CR44","doi-asserted-by":"publisher","first-page":"e2123019","DOI":"10.1001\/jamanetworkopen.2021.23019","volume":"4","author":"B Saloner","year":"2021","unstructured":"Saloner B, Whitley P, LaRue L, Dawson E, Huskey A. Polysubstance use among patients treated with buprenorphine from a national urine drug test database. JAMA Network Open. 2021;4(9):e2123019. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.23019.","journal-title":"JAMA Network Open."},{"issue":"9358","key":"323_CR45","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","volume":"361","author":"J Kakko","year":"2003","unstructured":"Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(03)12600-1.","journal-title":"Lancet"},{"issue":"3","key":"323_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-s","volume":"9","author":"AT McLellan","year":"1992","unstructured":"McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199\u2013213. https:\/\/doi.org\/10.1016\/0740-5472(92)90062-s.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"323_CR47","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1097\/ALN.0000000000000170","volume":"120","author":"KY Chen","year":"2014","unstructured":"Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014;120(5):1262\u201374. https:\/\/doi.org\/10.1097\/ALN.0000000000000170.","journal-title":"Anesthesiology"},{"issue":"3 Suppl","key":"323_CR48","doi-asserted-by":"publisher","first-page":"ES59","DOI":"10.36076\/ppj.2012\/15\/ES59","volume":"15","author":"J Daitch","year":"2012","unstructured":"Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J Jr. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012;15(3 Suppl):ES59-66.","journal-title":"Pain Physician"},{"issue":"3","key":"323_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0376-8716(98)00028-3","volume":"51","author":"S Darke","year":"1998","unstructured":"Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253\u201368. https:\/\/doi.org\/10.1016\/s0376-8716(98)00028-3.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"323_CR50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/002204261004000210","volume":"40","author":"DA Murphy","year":"2010","unstructured":"Murphy DA, Hser Y-I, Huang D, Brecht M-L, Herbeck DM. Self-report of longitudinal substance use: a comparison of the UCLA Natural History Interview and the Addiction Severity Index. J Drug Issues. 2010;40(2):495\u2013516.","journal-title":"J Drug Issues"},{"issue":"4","key":"323_CR51","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.addbeh.2009.12.006","volume":"35","author":"LE Napper","year":"2010","unstructured":"Napper LE, Fisher DG, Johnson ME, Wood MM. The reliability and validity of drug users\u2019 self reports of amphetamine use among primarily heroin and cocaine users. Addict Behav. 2010;35(4):350. https:\/\/doi.org\/10.1016\/j.addbeh.2009.12.006.","journal-title":"Addict Behav"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00323-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00323-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00323-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T06:32:52Z","timestamp":1658989972000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00323-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00323-4","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by Alberta Health Services organizational ethics review overseen by Alberta Innovates ARECCI (A pRoject Ethics Community Consensus Initiative).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}